Publisher
Springer International Publishing
Reference76 articles.
1. Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089–95.
2. Agid Y, Destee A, Durif F, Montastruc JL, Pollak P. Tolcapone, bromocriptine, and Parkinson’s disease. French Tolcapone Study Group. Lancet. 1997;350(9079):712–3.
3. Agid Y, Destee A, Durif F, Montastruc JL, Pedarriosse AM, Deptula D, et al. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord. 1999;14(1):38–44.
4. Agid Y, Oertel W, Factor S. Entacapone to tolcapone switch study: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord. 2005;20:S94.
5. Almeida L, Rocha JF, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139–51.